www.medical-devices.tech
06
'23
Written on Modified on
Baxter News
BAXTER LAUNCHES ZOSYN PREMIX IN THE US
The launch supports Baxter’s ongoing efforts to expand its anti-infective portfolio to increase access to essential medications and advance patient care.
Baxter International Inc. recently announced the U.S. launch of ZOSYN (piperacillin and tazobactam) Injection. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.
The use of premixes, or ready-to-use formats of standard doses of commonly prescribed drugs, may offer operational efficiencies for healthcare providers. Compounding a drug for patient use is a multi-step, manual process that requires oversight by pharmacy staff. A ready-to-use product like Zosyn premix can simplify the preparation process and help improve patient safety by reducing the chance of contamination and avoiding potential dosing errors that may occur when medications are compounded.
Baxter will sell Zosyn premix in 2.25 g in 50 mL, 3.375 g in 50 mL, and 4.5 g in 100mL presentations. Like other medications in Baxter’s premix portfolio, Zosyn premix uses Baxter’s proprietary Galaxy container technology. Galaxy is a non-PVC and non-DEHP system that enables premixed medications to have a longer shelf life.
www.baxter.com
